| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biomarker data, enhanced therapeutic data and insights will enable biopharmaceutical innovation and physician support through informed decision-making
IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of each patient, helping to optimize treatment outcomes and advance the standard of care in oncology. These advancements further strengthen IntrinsiQ's capabilities to deliver actionable insights that support better patient outcomes and drive innovation in specialty care.
Through its strong relationships and broad reach into community providers' operations and patient treatments, IntrinsiQ provides manufacturers with a complete picture of how therapies are being utilized across the healthcare ecosystem, showing the full story of what's happening once their therapies reach the market. This data, along with insights from physicians and clinical care team members, is critical in enabling pharmaceutical companies to conduct targeted outreach and education – helping improve patient outcomes.
As the life sciences industry continues its rapid growth, specialty clinicians working in various therapeutic areas recently reported feeling overwhelmed by the pace of innovation.
Posted In: COR
